An Infant-Type Hemispheric Glioma With SOX5::ALK: A Novel Fusion
Journal of the National Comprehensive Cancer Network · 2024-02 · 22 (1)
DOI: 10.6004/jnccn.2023.7102 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-02. Verfasst von Chia Chin Tsai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Taipei Medical University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Infant-type hemispheric glioma (IHG) is a rare pediatric brain tumor with variable response to chemotherapy and radiotherapy. Molecular insights into IHG can be useful in identifying potentially active targeted therapy. A male fetus was found to have congenital hydrocephalus at the gestational age of 37 weeks. Fetal MRI showed a 2.6 × 2.0-cm tumor located at the frontal horn of the left lateral ventricle, involving the left basal nuclei and thalamus. Tumor biopsy at the age of 2 days revealed an IHG consisting of spindle tumor cells with strong expression of GFAP and ALK. Targeted RNA sequencing detected a novel fusion gene of SOX5::ALK . After initial chemotherapy with cyclophosphamide, carboplatin, and etoposide for 2 cycles, the tumor size progressed markedly and the patient underwent a subtotal resection of brain tumor followed by treatment with lorlatinib, an ALK tyrosine kinase inhibitor with central nervous system (CNS) activity. After 3 months of treatment, reduction of tumor size was observed. After 14 months of treatment, partial response was achieved, and the infant had normal growth and development. In conclusion, we identified a case of congenital IHG with a novel SOX5::ALK fusion that had progressed after chemotherapy and showed partial response and clinical benefit after treatment with the CNS-active ALK inhibitor lorlatinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Taipei Medical University Hospital, Taipei, Taiwan.
- Department of Pathology, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, Zhonghe, New Taipei, Taiwan.
- Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Department of Medical Imaging, Taipei Medical University Hospital, Taipei, Taiwan.
- Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.
Zitieren
APA
Tsai, C. C., Huang, M. H., Fang, C. L., Hsieh, K. L., Hsieh, T. H., Ho, W. L., Chang, H., Tsai, M. L., Kao, Y. C., Miser, J. S., Wong, T. T., Su, M. Y., & Liu, Y. L. (2024). An Infant-Type Hemispheric Glioma With SOX5::ALK: A Novel Fusion. Journal of the National Comprehensive Cancer Network, 22(1). https://doi.org/10.6004/jnccn.2023.7102
Vancouver
Tsai CC, Huang MH, Fang CL, Hsieh KL, Hsieh TH, Ho WL, et al. An Infant-Type Hemispheric Glioma With SOX5::ALK: A Novel Fusion. Journal of the National Comprehensive Cancer Network. 2024;22(1). doi:10.6004/jnccn.2023.7102
BibTeX
@article{Tsai2024,
author = {Tsai, Chia Chin and Huang, Man-Hsu and Fang, Chia-Lang and Hsieh, Kevin Li-Chun and Hsieh, Tsung-Han and Ho, Wan-Ling and Chang, Hsi and Tsai, Min-Lan and Kao, Yu-Chien and Miser, James S and Wong, Tai-Tong and Su, Min-Yu and Liu, Yen-Lin},
title = {An Infant-Type Hemispheric Glioma With SOX5::ALK: A Novel Fusion},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
volume = {22},
number = {1},
doi = {10.6004/jnccn.2023.7102}
}
EUVIMED